Compare Stocks: AUTL, MAZE, CMPS, and NTLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.82 +22.1%	$1.57	$1.18 ▼ $2.52	$484.40M	2.04	1.65 million shs	13.37 million shs
CMPS Compass Pathways	$11.25 -0.9%	$12.53	$3.97 ▼ $15.40	$1.52B	2.47	3.74 million shs	2.77 million shs
MAZE Maze Therapeutics	$27.33 +1.5%	$27.36	$12.81 ▼ $53.65	$1.51B	2.14	680,364 shs	311,710 shs
NTLA Intellia Therapeutics	$10.77 +0.8%	$13.85	$7.95 ▼ $28.25	$1.50B	1.81	5.47 million shs	3.31 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	+2.76%	-5.70%	+1.36%	-36.60%
CMPS Compass Pathways	0.00%	+0.80%	-16.67%	+25.97%	+161.52%
MAZE Maze Therapeutics	0.00%	-2.75%	-13.88%	-1.27%	+80.67%
NTLA Intellia Therapeutics	0.00%	-0.47%	-39.18%	-19.46%	-7.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.82 +22.1%	$1.57	$1.18 ▼ $2.52	$484.40M	2.04	1.65 million shs	13.37 million shs
CMPS Compass Pathways	$11.25 -0.9%	$12.53	$3.97 ▼ $15.40	$1.52B	2.47	3.74 million shs	2.77 million shs
MAZE Maze Therapeutics	$27.33 +1.5%	$27.36	$12.81 ▼ $53.65	$1.51B	2.14	680,364 shs	311,710 shs
NTLA Intellia Therapeutics	$10.77 +0.8%	$13.85	$7.95 ▼ $28.25	$1.50B	1.81	5.47 million shs	3.31 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	+2.76%	-5.70%	+1.36%	-36.60%
CMPS Compass Pathways	0.00%	+0.80%	-16.67%	+25.97%	+161.52%
MAZE Maze Therapeutics	0.00%	-2.75%	-13.88%	-1.27%	+80.67%
NTLA Intellia Therapeutics	0.00%	-0.47%	-39.18%	-19.46%	-7.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.89	Moderate Buy	$8.75	380.77% Upside
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	107.62% Upside
MAZE Maze Therapeutics	3.00	Buy	$66.00	141.49% Upside
NTLA Intellia Therapeutics	2.30	Hold	$20.19	87.44% Upside

Current Analyst Ratings Breakdown

Latest AUTL, MAZE, CMPS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/27/2026	CMPS Compass Pathways	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$13.00
7/27/2026	CMPS Compass Pathways	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$13.00
7/17/2026	CMPS Compass Pathways	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	NTLA Intellia Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform	$9.00
7/10/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $17.00
7/8/2026	CMPS Compass Pathways	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$70.00
7/8/2026	CMPS Compass Pathways	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$21.00
7/7/2026	CMPS Compass Pathways	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $21.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$92.62M	5.23	N/A	N/A	$0.67 per share	2.72
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
MAZE Maze Therapeutics	$20M	75.63	N/A	N/A	$7.38 per share	3.70
NTLA Intellia Therapeutics	$67.67M	22.24	N/A	N/A	$5.80 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.09	N/A	N/A	N/A	-311.98%	-128.59%	-46.25%	8/11/2026 (Estimated)
CMPS Compass Pathways	-$287.86M	-$3.15	N/A	N/A	N/A	N/A	-31.07%	-11.40%	8/5/2026 (Confirmed)
MAZE Maze Therapeutics	-$131.12M	-$2.53	N/A	N/A	N/A	N/A	-36.62%	-31.78%	N/A
NTLA Intellia Therapeutics	-$412.69M	-$3.54	N/A	N/A	N/A	-597.04%	-57.47%	-46.24%	8/6/2026 (Estimated)

Latest AUTL, MAZE, CMPS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.22	N/A	N/A	N/A	$29.74 million	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.8017	N/A	N/A	N/A	$12.98 million	N/A
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	AUTL Autolus Therapeutics	-$0.29	-$0.27	+$0.02	-$0.27	$26.27 million	$26.22 million
5/13/2026	Q1 2026	CMPS Compass Pathways	-$0.45	-$0.30	+$0.15	-$0.30	N/A	N/A
5/12/2026	Q1 2026	MAZE Maze Therapeutics	-$0.43	-$0.45	-$0.02	-$0.45	N/A	$20.00 million
5/11/2026	Q1 2026	NTLA Intellia Therapeutics	-$0.92	-$0.81	+$0.11	-$0.81	$13.81 million	$15.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	5.80	5.28
CMPS Compass Pathways	0.15	3.32	3.32
MAZE Maze Therapeutics	0.11	17.88	17.88
NTLA Intellia Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CMPS Compass Pathways	46.19%
MAZE Maze Therapeutics	N/A
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CMPS Compass Pathways	2.82%
MAZE Maze Therapeutics	5.30%
NTLA Intellia Therapeutics	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.16 million	197.75 million	Optionable
CMPS Compass Pathways	120	134.95 million	131.14 million	Optionable
MAZE Maze Therapeutics	121	55.35 million	52.41 million	N/A
NTLA Intellia Therapeutics	600	139.72 million	134.83 million	Optionable

AUTL, MAZE, CMPS, and NTLA Headlines

Recent News About These Companies

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Analysts

August 3 at 4:15 AM | americanbankingnews.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages

August 3 at 4:13 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Makes New Investment in Intellia Therapeutics, Inc. $NTLA

July 31 at 3:12 AM | marketbeat.com

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

July 30, 2026 | globenewswire.com

Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Himension Capital Singapore PTE. LTD. Sells 149,022 Shares of Intellia Therapeutics, Inc. $NTLA

July 22, 2026 | marketbeat.com

Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA

July 21, 2026 | marketbeat.com

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

July 20, 2026 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)

July 17, 2026 | theglobeandmail.com

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential

July 14, 2026 | seekingalpha.com

Sumitomo Mitsui Trust Group Inc. Lowers Position in Intellia Therapeutics, Inc. $NTLA

July 14, 2026 | marketbeat.com

Canal Insurance CO Acquires 130,000 Shares of Intellia Therapeutics, Inc. $NTLA

July 14, 2026 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 7.1% - Here's Why

July 13, 2026 | marketbeat.com

Wedbush Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $17.00

July 10, 2026 | marketbeat.com

Y Intercept Hong Kong Ltd Buys New Shares in Intellia Therapeutics, Inc. $NTLA

July 10, 2026 | marketbeat.com

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success

July 9, 2026 | finance.yahoo.com

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

July 9, 2026 | zacks.com

Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns

July 9, 2026 | finance.yahoo.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Hold" by Analysts

July 9, 2026 | marketbeat.com

A new CRISPR DNA shredder could change gene-editing -- what it means for CRISPR Therapeutics

July 8, 2026 | msn.com

A new CRISPR DNA shredder could change gene-editing -- what it means for CRISPR Therapeutics

July 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, MAZE, CMPS, and NTLA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.82 +0.33 (+22.15%)

Closing price 04:00 PM Eastern

Extended Trading

$1.85 +0.03 (+1.65%)

As of 05:05 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Compass Pathways NASDAQ:CMPS

$11.25 -0.10 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$11.43 +0.18 (+1.59%)

As of 05:06 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Maze Therapeutics NASDAQ:MAZE

$27.33 +0.41 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$27.31 -0.02 (-0.07%)

As of 04:13 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Intellia Therapeutics NASDAQ:NTLA

$10.77 +0.09 (+0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$10.76 -0.01 (-0.14%)

As of 05:06 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, MAZE, CMPS, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, MAZE, CMPS, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, MAZE, CMPS, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, MAZE, CMPS, and NTLA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Compass Pathways NASDAQ:CMPS

Maze Therapeutics NASDAQ:MAZE

Intellia Therapeutics NASDAQ:NTLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, MAZE, CMPS, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, MAZE, CMPS, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, MAZE, CMPS, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, MAZE, CMPS, and NTLA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Compass Pathways NASDAQ:CMPS

Maze Therapeutics NASDAQ:MAZE

Intellia Therapeutics NASDAQ:NTLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools